Highlights and Quick Summary
- Non-operating Income/Expense for the quarter ending September 29, 2021 was $265 Million (a -83.72% decrease compared to previous quarter)
- Year-over-year quarterly Non-operating Income/Expense decreased by -95.16%
- Annual Non-operating Income/Expense for 2020 was $10.1 Billion (a 123.62% increase from previous year)
- Annual Non-operating Income/Expense for 2019 was $4.51 Billion (a -15.29% decrease from previous year)
- Annual Non-operating Income/Expense for 2018 was $5.32 Billion (a 182.39% increase from previous year)
- Twelve month Non-operating Income/Expense ending September 29, 2021 was $7.36 Billion (a -3.2% decrease compared to previous quarter)
- Twelve month trailing Non-operating Income/Expense increased by 82.29% year-over-year
Trailing Non-operating Income/Expense for the last four month:
| 29 Sep '21 | 29 Jun '21 | 30 Mar '21 | 30 Dec '20 |
|---|---|---|---|
| $7.36 Billion | $7.6 Billion | $4.53 Billion | $4.04 Billion |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Non-operating Income/Expense of AbbVie Inc.
Most recent Non-operating Income/Expenseof ABBV including historical data for past 10 years.Interactive Chart of Non-operating Income/Expense of AbbVie Inc.
AbbVie Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $265.0 | $1,628.0 | $-12.0 | – | – |
| 2020 | $5,480.0 | $508.0 | $-1,445.0 | $-505.0 | $10,083.0 |
| 2019 | $-882.0 | $-616.0 | $-2,593.0 | $-466.0 | $4,509.0 |
| 2018 | $68.0 | $-398.0 | $-750.0 | $-106.0 | $5,323.0 |
| 2017 | $-589.0 | $-599.0 | $-309.0 | $-321.0 | $1,885.0 |
| 2016 | $-316.0 | $-347.0 | $-291.0 | $-502.0 | $423.0 |
| 2015 | $-189.0 | $-238.0 | $-174.0 | $-291.0 | $-892.0 |
| 2014 | $-622.0 | $-273.0 | $-82.0 | $-65.0 | $-1,042.0 |
| 2013 | $-96.0 | $-85.0 | $-85.0 | $-66.0 | $-332.0 |
| 2012 | $-108.0 | $8.0 | $-20.0 | $28.0 | $-92.0 |
| 2011 | – | – | $14.12 | $33.89 | $48.0 |
| 2010 | – | – | – | – | $119.0 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.